Emilio Bajetta

Q: What Schools Are Affiliated With Emilio Bajetta

Emilio Bajetta is affiliated with the following schools: University of Duisburg-Essen, Medical University of Vienna, University of Milan, University of Messina, Autonomous University of Barcelona, University of Oxford, Charles University, Vita-Salute San Raffaele University, University of Florence, Sapienza University of Rome

Emilio Bajetta's AcademicInfluence.com Rankings

Emilio Bajetta

Engineering

#7500

World Rank

#8876

Historical Rank

Biomedical Engineering

#764

World Rank

#776

Historical Rank

engineering Degrees

Emilio Bajetta

Philosophy

#9956

World Rank

#13590

Historical Rank

Logic

#6907

World Rank

#8467

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Emilio Bajetta's Degrees

PhD Biomedical Engineering University of Milan
Doctorate Medicine University of Milan

Why Is Emilio Bajetta Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Emilio Bajetta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (2007) (2234)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. (2004) (1787)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial (2009) (1366)
Combination chemotherapy as an adjuvant treatment in operable breast cancer. (1976) (1273)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. (2001) (1025)
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. (2001) (1002)
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (1998) (994)
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial (2007) (836)
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. (2010) (784)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. (2007) (578)
Interleukin-12: Biological Properties and Clinical Application (2007) (564)
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (2000) (527)
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. (2002) (513)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. (2012) (471)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. (2009) (412)
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. (2004) (398)
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. (2000) (318)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. (2007) (318)
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors (1999) (294)
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group (1996) (287)
Activity of sunitinib in patients with advanced neuroendocrine tumors. (2009) (267)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study (2008) (253)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. (2008) (214)
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? (2007) (211)
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. (2005) (198)
Metastatic melanoma: chemotherapy. (2002) (170)
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. (1998) (164)
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. (2008) (163)
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. (2001) (163)
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma (1982) (151)
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. (2011) (148)
5‐fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors (1998) (141)
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma (2004) (138)
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. (1994) (138)
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. (2002) (134)
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. (1996) (134)
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. (2011) (132)
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon‐alpha‐2a: A study by the Italian trials in Medical Oncology Group (1993) (128)
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. (2011) (114)
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. (2002) (114)
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. (1982) (110)
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. (2010) (108)
Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. (2000) (106)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. (2006) (106)
Are surgical adjuvant trials altering the course of breast cancer? (1978) (104)
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. (2008) (100)
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial (2010) (99)
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study (2009) (96)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors (2009) (93)
Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). (2006) (92)
Clinical trials with bleomycin in lymphomas and in solid tumors. (1972) (91)
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab (2007) (88)
Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases (2011) (88)
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? (2005) (87)
A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. (1995) (84)
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. (1999) (80)
Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. (1995) (78)
Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) (2005) (72)
A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer. (2012) (68)
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. (1995) (67)
Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study (2014) (67)
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors (2006) (67)
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial (2011) (66)
Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. (2004) (65)
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. (1999) (64)
Treatment of cancer-related anemia with epoetin alfa: a review. (2004) (61)
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. (2013) (58)
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. (2014) (58)
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. (1999) (58)
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. (2010) (57)
Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. (1999) (57)
Pathological features as predictors of recurrence after radical resection of gastric cancer (2006) (56)
Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens (2013) (55)
Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. (2003) (55)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (53)
Ten‐year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus (2002) (52)
Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (2007) (51)
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (2011) (51)
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. (2018) (50)
Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors (2010) (48)
Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis (2008) (47)
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. (2002) (46)
Clinical use of adriamycin in advanced testicular cancer. (1972) (46)
Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. (1995) (45)
A Pilot Safety Study of Capecitabine, A New Oral Fluoropyrimidine, in Patients with Advanced Neoplastic Disease (1996) (44)
Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone (2009) (44)
Treatment of carcinoid syndrome with recombinant interferon alpha-2a. (1993) (43)
The minimal effective exemestane dose for endocrine activity in advanced breast cancer. (1997) (43)
Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges (2011) (42)
Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma (2004) (41)
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer (2016) (40)
Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. (1979) (40)
Neuroendocrine tumors of unknown primary site: Gold dust or misdiagnosed neoplasms? (2011) (39)
Laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease. (1975) (39)
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study (2007) (38)
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma. (1994) (38)
Sequential pathologic staging of untreated non‐Hodgkin's lymphomas by laparoscopy and laparotomy combined with marrow biopsy (1977) (38)
A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma (1993) (38)
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. (2000) (37)
A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma (2002) (36)
4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma (2007) (36)
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. (2006) (36)
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT (2014) (35)
Sorafenib in Hepatocellular Carcinoma (2009) (35)
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. (2007) (35)
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. (2000) (34)
Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy. (1988) (34)
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. (2004) (33)
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. (2004) (33)
Gemcitabine plus vinorelbine as first‐line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial (2000) (32)
Genitourinary tumors, non-prostate (2012) (31)
The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels (1997) (31)
Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. (2004) (30)
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial. (2000) (29)
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials (2012) (29)
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. (1993) (27)
Mitoxantrone: An Active Agent in Refractory Non‐Hodgkin's Lymphomas (1988) (27)
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. (2013) (26)
Phase II Study of Interferon α‐2a and Dacarbazine in Advanced Melanoma (1990) (26)
Pulmonary Carcinoid Tumours: Indolent but Not Benign (2008) (26)
Treatment of advanced malignant melanoma with vinblastine, bleomycin, and cisplatin. (1982) (25)
The cost of unresectable stage III or stage IV melanoma in Italy (2012) (25)
Update on the treatment of neuroendocrine tumors (2003) (25)
Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. (1995) (24)
Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma (2008) (24)
Classic Kaposi's Sarcoma: A Review of 90 Cases (1992) (24)
Herpes zoster-varicella infection in malignant lymphomas. Influence of splenectomy and intensive treatment. (1975) (24)
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (24)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (24)
Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease. (1976) (23)
Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis. (2011) (23)
Bleomycin alone and in Combination with Methotrexate in the Treatment of Carcinoma of the Esophagus. (1974) (23)
Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. (2012) (22)
252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) (2009) (22)
Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study (2007) (22)
Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC) (2008) (22)
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. (1994) (21)
Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research. (1994) (21)
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. (2009) (21)
Treatment of Metastatic Breast Cancer with Cyclophosphamide, Methotrexate, Vincristine and Fluorouracil. (1973) (21)
Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study. (1998) (20)
New trends in the treatment of malignant melanoma. (1978) (20)
Fine Needle Percutaneous Intratumoral Chemotherapy under Ultrasound Guidance: A Feasibility Study (1986) (20)
Laparoscopy and laparotomy in staging Hodgkin's and non-Hodgkin's lymphoma. (1976) (20)
Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. (1994) (19)
Salvage Treatment After rInterferon α-2a in Advanced Neuroendocrine Tumors (1993) (19)
Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. (1992) (18)
Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study (1999) (18)
Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review (2006) (18)
A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (2011) (17)
Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens (2014) (17)
Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report. (2008) (17)
The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. (1996) (16)
Controlled Study with Imidazole Carboxamide (DTIC), DTIC + Bacillus Calmette-Guérin (BCG), and DTIC + Corynebacterium Parvum in Advanced Malignant Melanoma (1984) (16)
Liver Assessment in Women Receiving Adjuvant CMF Chemotherapy 1 (1981) (16)
Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update (2017) (16)
Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. (1995) (16)
Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. (2008) (16)
Efficacy of Treatment with Irinotecan and Oxaliplatin Combination in FU-Resistant Metastatic Colorectal Cancer Patients (2004) (16)
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors (2018) (16)
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. (2003) (16)
Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting (2008) (15)
Steroidal aromatase inhibitors in elderly patients. (2000) (15)
Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma (2007) (15)
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. (2015) (15)
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). (1999) (15)
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis (2015) (15)
Induction Chemotherapy With Carboplatin/Paclitaxel Followed by Surgery or Standard Radiotherapy and Concurrent Daily Low-Dose Cisplatin for Locally Advanced Non-Small Cell Lung cancer (NSCLC) (2003) (15)
Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. (1996) (15)
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. (2008) (14)
Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan. (1993) (14)
Medical Treatment of Neuroendocrine Tumors (1993) (14)
Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer (1994) (14)
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? (2003) (14)
Hormonal Regulation of MUC1 Expression (1999) (14)
Single-Agent Chemotherapy with Vinorelbine for Pretreated or Metastatic Squamous Cell Carcinoma of the Esophagus (2001) (14)
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases (2017) (13)
Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. (2010) (13)
Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma. (1993) (13)
Aromatase Inhibitors in the Treatment of Postmenopausal Breast Cancer (1999) (13)
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. (1997) (13)
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. (1997) (13)
Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition (2006) (13)
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. (2003) (13)
Melanoma and other skin tumors (2012) (13)
Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo‐leucovorin in untreated patients with advanced colorectal carcinoma (1996) (12)
Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma. (2004) (12)
An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. (1995) (12)
Pemetrexed in gastric cancer: clinical experience and future perspectives. (2002) (12)
Efficacy and safety of RAD001 in advanced biliary tract cancer (BTC) patients (pts) progressing after first-line chemotherapy: A phase II study. (2010) (12)
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. (2004) (12)
Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer (2001) (12)
Feasibility Study of Biweekly Capecitabine, Oxaliplatin, and Irinotecan in Patients with Untreated Advanced Gastric Cancer (2009) (12)
Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. (1994) (12)
Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. (1993) (12)
Clinical Classification and Survival in Chronic Lymphocytic Leukemia (1979) (12)
Cytarabine and cisplatin in advanced malignant melanoma. (1986) (11)
In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). (2005) (11)
Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer (1998) (11)
Renal Cancer Treatment: A Review of the Literature (2003) (11)
Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines. (1993) (11)
Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer (2016) (11)
Methotrexate (NSC-740) and bleomycin (NSC-125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix. (1973) (11)
Merkel Cell Carcinoma after Liver Transplantation: A Case Report (2007) (11)
Adriamycin plus Bleomycin versus Cyclophosphamide plus Vincristine in Advanced Carcinoma of the Uterine Cervix (1976) (11)
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. (2004) (11)
Safety profile and treatment response of everolimus in different solid tumors: an observational study. (2014) (11)
Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan. (1980) (11)
Raltitrexed plus Oxaliplatin in the Treatment of Metastatic Colorectal Cancer (2004) (11)
Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study (2001) (10)
The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor. (2019) (10)
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors (2022) (10)
A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma (2001) (10)
Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan. (1981) (10)
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. (2002) (10)
A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. (1984) (10)
Usefulness of Chest and Skeletal Survey to Assess the Time of Relapse in Breast Cancer (1981) (10)
Integrated Therapeutic Strategies for Anaplastic Thyroid Carcinoma (2003) (9)
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients (2009) (9)
Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer: A Phase II Study (2014) (9)
Formestane: effective therapy in postmenopausal women with advanced breast cancer. (1994) (9)
Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer (1995) (9)
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients (2002) (9)
New clinical trials for the treatment of neuroendocrine tumors. (2000) (9)
A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. (2016) (9)
Adjuvant treatment for elderly patients with colon cancer. An observational study. (2008) (9)
The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers (2000) (9)
Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report (2010) (9)
Oxaliplatin doublets in non-small cell lung cancer: a literature review. (2008) (9)
L'imaging radioisotopico dei tumori neuroendocrini. Quale radiofarmaco e quale metodica? (2001) (8)
A dose‐finding study of lanreotide (A somatostatin analog) in patients with colorectal carcinoma (1996) (8)
Capecitabine Chemoradiation for Rectal Cancer after Curative Surgery (2006) (8)
Development of a Rapid and Ultrasensitive RIA Method for Estrogen (E2, E1, E1-S) Determination with Selective Solid Phase Extraction (1997) (8)
Safety and activity of Capecitabine in elderly patients with advanced breast cancer (2001) (8)
Erratum: Treatment of carcinoid syndrome with recombinant interferon alpha-2a (Acta Oncologica Volume 32:2 (1993) 235-8) (1993) (8)
Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT (1999) (8)
Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma (2008) (8)
Activity and safety of capecitabine and irinotecan (CPT-11) in association as first line chemotherapy in advanced colorectal cancer (ACRC) (2001) (8)
Preliminary Phase I Evaluation of Bleomycin, a New Antitumor Antibiotic (1971) (8)
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. (2005) (8)
[Preliminary study of phase I of bleomycin, a new anti-tumor drug]. (1971) (8)
[Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]. (2001) (7)
Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group. (2013) (7)
Current Treatments of Neuroendocrine Tumors Role of Biotherapy and Chemotherapy (2003) (7)
Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome (2007) (7)
Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). (2010) (7)
Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan. (1973) (7)
The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. (1994) (7)
New perspectives in the treatment of neuroendocrine tumours. (2012) (7)
Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas. (1985) (6)
Prospective randomized trial in advanced malignant melanoma with cis‐platinum, vindesine, and etoposide vs. cis‐platinum, vindesine, and lomustine (1985) (6)
Recombinant-human-erythropoietin (rhuepo) in the treatment of anemia associated with solid tumors with or without bone-marrow infiltration. (1993) (6)
Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. (1995) (6)
837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma (2003) (6)
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration (2011) (6)
Hormone therapy in advanced breast carcinoma: present and future trends. (1994) (6)
An Intensive Treatment with Mitoxantrone and Ifosfamide in Second-Line Therapy of Epithelial Ovarian Cancer (1994) (6)
Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. (1993) (6)
Advances in diagnosis and therapy of neuroendocrine tumors (2001) (6)
FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. (1998) (6)
Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response? (2007) (6)
National integration of European standards. (2007) (5)
Present status and future perspectives of adjuvant treatment of cutaneous malignant melanoma (1983) (5)
Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma. (2010) (5)
Controlled studies with bleomycin in solid tumors and lymphomas. (1976) (5)
CVP versus BACOP Chemotherapy Sequentially Combined with Irradiation in Stage I–II Diffuse Non-Hodgkin’s Lymphomas (1985) (5)
Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. (1995) (5)
Pitfalls in neuroendocrine tumor diagnosis (2009) (5)
Prostate adenocarcinoma presenting with supraclavicular node enlargement: report of a case. (2008) (5)
Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma. (2014) (4)
Ovarian Ablation for Premenopausal Early-Stage Breast Cancer: An Update (2000) (4)
Front line chemotherapy with four different schedules of gemcitabine and carboplatin in stage IV non-small cell lung cancer (NSCLC) (2001) (4)
Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors (2004) (4)
Prostate Adenocarcinoma Presenting with Supraclavicular Node Enlargement: Report of a Case (2008) (4)
7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial (2009) (4)
Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy (2004) (4)
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). (2011) (4)
Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma. (1990) (4)
Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. (2008) (4)
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron (2009) (4)
Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer (1999) (4)
From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours (2011) (4)
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine (2004) (4)
Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer (2004) (4)
In regard to Kagan: The multidisciplinary clinic. Author's reply (2005) (4)
[A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer]. (2001) (4)
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes. (2009) (4)
Adriamycin (ADM) plus bleomycin (BLM) versus CTX plus VCR in advanced carcinoma of the cervix (1974) (4)
[New strategies in the treatment of esophageal cancer]. (2002) (4)
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM). (2009) (3)
Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC). (2010) (3)
Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy. (2007) (3)
Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma? (2010) (3)
Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial. (2016) (3)
Formestane: an effective first-line endocrine treatment for advanced breast cancer (2005) (3)
Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. (1993) (3)
Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer (2011) (3)
Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. (2008) (3)
[New drugs in the therapy of colorectal cancer]. (2001) (3)
Efficacy of Epoetin Alfa in a Retrospective Non-stratified Subgroup Analysis of a Breast Cancer Cohort Receiving Non-platinum Chemotherapy (2004) (3)
Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: Short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA) (2001) (3)
Epirubicin Plus Medroxyprogesterone as Second‐Line Treatment of Advanced Prostatic Cancer: A Study by the Italian Trials in Medical Oncology Group (1995) (3)
Adriamycin in Combination and in Combined Treatment Modalities. (1974) (3)
Adjuvant Oophorectomy versus CMF in Premenopausal Node-Positive Breast Cancer: Long-Term Results of an Experience at the Milan Cancer Institute (2000) (3)
Second-Generation Aromatase Inhibitors (1995) (3)
Integrated Treatment with Doxifluridine and Radiotherapy in Recurrent or Primary Unresectable Rectal Cancer. A Feasibility Study (1999) (3)
117 Oxaliplatin plus capecitabine in advanced neuroendocrine tumours (NETs): Is the new WHO classification applicable to daily practice? (2003) (3)
NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study (2008) (3)
A dose finding study with erlotinib in combination to irinotecan and capecitabine in metastatic colorectal cancer (mCRC) patients. (2006) (3)
Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results (2008) (3)
Home treatment with interleukin 2 and beta-interferon in patients with colorectal cancer and hepatocellular carcinoma. (1994) (3)
Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes (2009) (2)
Chemotherapy of advanced malignant-melanoma (review). (1994) (2)
Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment. (2014) (2)
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. (1997) (2)
Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors. (2003) (2)
451 Elderly patients with advanced breast cancer: safety and efficacy of capecitabine (2003) (2)
Doxifluridine: an active agent in advanced gastrointestinal cancer. (1995) (2)
ITACA-S (Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment versus a 5-FU/LV regimen for radically resecate gastric cancer. Tolerability and feasibility of a randomized study (2010) (2)
Neuroendocrine tumors (NETs). (2009) (2)
Differences in activity of mitoxantrone (DHAD) plus ifosfamide (IFO) according to previous platinum-compound (PC) responsiveness in advanced ovarian cancer (AOC). An I.T.M.O. group study (1993) (2)
Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma (2010) (2)
Pharmacological therapy of neuroendocrine tumors. (2010) (2)
Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancer. (1994) (2)
Erratum: Informal caregiving burden in advance non-small cell lung cancer: The HABIT study (Journal of Thoracic Oncology (2007) 2, 6, (475-480)) (2007) (2)
Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET) : A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data (2014) (2)
Is Irinotecan Plus Docetaxel Useful as Second-Line Therapy in Advanced Non-small Cell Lung Cancer? (2008) (2)
Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial. (2013) (2)
[Adjuvant chemotherapy following liver metastasis resection in neoplasms of the colorectum]. (1996) (1)
Guidelines to modern treatment of non-Hodgkin's lymphomas. (1987) (1)
Disodium Pamidronate in the Treatment of Bone Metastases from Breast Cancer (1993) (1)
Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) (2022) (1)
Pemetrexed disodium (Alimta™) with folic acid (FA) in advanced or metastatic gastric cancer (2001) (1)
Level of circulating endothelial cells as new biomarker in patients with multiple myeloma, treated with bortezomib-pegylated liposomal doxorubicin-dexamethasone combination. (2006) (1)
2320 : Patient’s Fantasies and Worries About Radiation Therapy for Prostate Cancer During the Decision Making Phase (2006) (1)
Management of infections in immunocompromised cancer patients. (1984) (1)
Vindesine (VDS) in Padua and Milan (1981) (1)
9. Pharmacological Therapy of Neuroendocrine Tumors (2010) (1)
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer. (1997) (1)
Systemic treatment of advanced malignant-melanoma (review). (1993) (1)
Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement (2018) (1)
9011 NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study (2009) (1)
3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials (2011) (1)
Reversal of Resistance to Doxifluridine and Fluorouracil in Metastatic Colorectal Cancer: The Role of High-Dose Folinic Acid (1992) (1)
Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial (2013) (1)
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (1)
The cost of unresectable stage III or stage IV melanoma in Italy (2012) (1)
4-Hydroxyandrostenedione (4-OHA) as first line treatment in postmenopausal patients with advanced breast cancer(ABC) (1993) (1)
History of Neuroendocrine Neoplasia (2021) (1)
Well-Differentiated Neuroendocrine Carcinoma of the Lung: A Case Report (1991) (1)
Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group. (1994) (1)
An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review (2010) (1)
Abstract B33: Osteopontin expression is an independent poor prognostic marker in gastric cancer radically resected. Preliminary report of translational study of ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) study. (2013) (1)
6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study (2011) (1)
New developments in breast cancer research (1991) (1)
Control of Emesis by a Low Dose of Ondansetron and Dexamethasone (1994) (1)
10 Results of the treatment with IL-12 in patients with malignant melanoma (1997) (1)
A multicentric randomized phase III study to evaluate the equivalence between lanreotide PR 60 mg vs lanreotide Autogel 120 mg in well-differentiated neuroendocrine tumours (NETs). (2004) (1)
Advanced Breast Cancer in Elderly Patients: Which Drug after Tamoxifen? (2002) (1)
Biological study of anastrozole in post-menopausal advanced breast cancer (ABC) patients: Effects on bone metabolism and oestrogen suppression (2001) (1)
Impressive objective response in a patient with extensive metastatic melanoma including the brain. (2007) (1)
Activity o f E xemestane i n M etastatic B reast C ancer After F ailure o f N onsteroidal A romatase I nhibitors: A P hase I I T rial (2000) (0)
[Chemotherapy of malignant melanoma]. (1973) (0)
Biological and clinical evaluation of Lanreotifle ( BIM 23014 ) , a somatostatin analogue , in the treatment of advanced breast cancer (0)
Chapter 10 – HODGKIN'S DISEASE: AN OVERVIEW AND ABVD STUDIES IN MILAN (1985) (0)
6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study (2011) (0)
Efficacy and Safety of Everolimus Plus Octreotide LAR in Patients With Colorectal Neuroendocrine Tumors (NET): Subgroup Analysis of the Phase III RADIANT-2 Trial: 394 (2011) (0)
Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report (2010) (0)
Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) : A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS) (2014) (0)
A Case Report of Richter's Syndrome with Review of the Literature (1973) (0)
A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (2015) (0)
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) (0)
5060 Comparable efficacy of low-dose (1,000 mg/m 2 b.i.d.) capecitabine and standard-dose (1,250 mg/m 2 b.i.d.) capecitabine administered for ≥6 weeks in older women with advanced breast cancer (2009) (0)
Experience of the NCI-Milan with DTIC plus interferon in the treatment of advanced melanoma: 112 (1993) (0)
c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients. (2002) (0)
O ral C apecitabine C ompared W ith I ntravenous Fluorouracil P lus L eucovorin i n P atients W ith M etastatic Colorectal C ancer: R esults o f a L arge P hase I II S tudy (2001) (0)
P-456 Gemcitabine (GEM) plus platinum analogues in advanced/metastatic NSCLC: Preliminary results of a randomized phase II three-arm multicentric study (2005) (0)
Systemic therapy of melanoma (1994) (0)
A Phase I 1 Study of Mitoxantrone Combined with Beta-Interferon in Unresectable Hepatocellular Carcinoma (2006) (0)
Evaluation of G-CSF activity given by intramuscolar (I.M.) route in ovarian cancer patients receiving mitoxantrone (DHAD) + ifosfamide (IFO) as second-line (SL) therapy (1993) (0)
Evolving perspectives on antiproliferative effects of octreotide treatment: the PROMID data (2010) (0)
Combinational chemotherapy and radiotherapy (2011) (0)
Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy (Italian Intergroup Adjuvant Chemotherapy of Adenocarcinoma of the Stomach-ITACA-S Trial). (2015) (0)
O . Group Study on Second-line Treatment in Advanced Epithelial Ovarian Cancer : an Attempt to Identify Clinical and Biological F actors Determining Prognosis (2015) (0)
Medical treatment and other combination regimens. (2007) (0)
Four-drug sequential regimen in advanced breast cancer (1987) (0)
452 Osteoprotegerin (OPG) and osteopontin (OPN): their usefulness in monitoring the Anastrzole (AN) treated advanced breast cancer (ABC) patients bearing bone metastases (2003) (0)
Contents Vol. 71, 2006 (2007) (0)
Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program (2012) (0)
705 Doxifluridine in patients with 5-FU resistant colorectal cancer (1995) (0)
Preliminary Study of the Bacterial Flora and Indications for Antibiotic Therapy in Cancer Patients (1973) (0)
[Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection]. (1996) (0)
Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. (1995) (0)
The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group (1997) (0)
Phase-ii trial of oral doxifluridine plus oral levo-leucovorin in unresectable hepatocellular-carcinoma. (1995) (0)
[Preliminary study of the bacterial flora and indications for the use of antibiotic therapy in cancer patients]. (1973) (0)
27 Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology divisions in Italy (2006) (0)
Medical treatment of hepatocarcinoma. (1992) (0)
Acknowledgement to Reviewers (2016) (0)
A randomized study with 4-hydroxyandrostenedione (4-OHA) in postmenopausal advanced breast cancer (ABC): Characteristics of responsive patients (1992) (0)
Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update. (2016) (0)
Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM) (2008) (0)
Could the Safety Profile of Everolimus be Different in Different Cancers? Fondazione IRCCS Istituto Nazionale Tumori (INT) Experience in Renal Cell Carcinoma, Neuroendocrine Tumors (NETS) and Biliary-Tract Cancers (2012) (0)
Safety and activity of sorafenib in advanced renal cell cancer: A single institution experience (2007) (0)
Subject Index Vol. 52,1995 (1995) (0)
Current Studies at the Milan Cancer Institute with Bleomycin-Containing Regimens for Malignant Lymphomas (1982) (0)
Combined RT-chemotherapy (CVP vs BACOP) in PS I-II diffuse non-Hodgkin's lymphomas (NHL) (1981) (0)
Multicenter phase II study of pemetrexed and oxaliplatin as first-line therapy in advanced gastric cancer. (2006) (0)
R01Phase II study of everolimus in combination with octreotide LAR as first line setting for patients with neuroendocrine tumors (I.T.M.O. study): a 5-years update (2015) (0)
376 Oral doxifluridine plus leucovorin in elderly patients with advanced breast cancer (1995) (0)
6510 Sequential therapy with FOLFIRI followed by docetaxel plus cisplatin: a promising adjuvant chemotherapy in gastric adenocarcinoma. 5-year follow-up results of the I.T.M.O. Group study (2009) (0)
719 Doxifluridine in advanced colorectal carcinoma. Parallel multicentre randomized phase II trial (1995) (0)
P.26 Adjuvant treatment for elderly patients with colon cancer in ten Italian medical oncology units (2007) (0)
6137 POSTER Biological Analysis of Phase II Study Evaluating the Activity of Cetuximab Combined to Oxaliplatin and Fluoropirimidine (TEGAFOX-E) as First Line Treatment in Metastatic Colorectal Cancer (mCRC) Pts by the Italian Trials in Medical Oncology (I.T.M.O.) Group (2011) (0)
The role of tamoxifen (T) in association with chemotherapy in metastatic melanoma (MM): 189 (1993) (0)
Procopio G,Verzoni E,Bracarda S,Ricci S,Sacco C,Ridolfi L,Porta C,Miceli R,Zilembo N,Bajetta E,Italian Trials in Medical Oncology (ITMO) group Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC (0)
Subject Index Vol. 71, 2006 (2007) (0)
963 Exemestane in postmenopausal patients with advanced breast cancer: A dose-finding study (1995) (0)
Phase II study of everolimus in combination with octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 4-year update. (2015) (0)
Neuroendocrine tumors: Preface (2010) (0)
Preoperative treatment with paclitaxel and carboplatin in locally advanced non small cell lung cancer (NSCLC): A phase II trial (2000) (0)
Letrozoleof its Use in Postmenopausal Women with Advanced Breast Cancer (1998) (0)
128Resection versus transplantation for liver metastases from neuroendocrine tumors (2000) (0)
9034 Medical treatment choices of over 1000 Italian patients affected by stage IIIB-IV NSCLC in routine clinical practice: results from the observational "SUN" (Survey on the lUng cancer maNagement) study on behalf of SUN study Group (2009) (0)
Erratum: Safety profile and treatment response of everolimus in different solid tumors: An observational study (Future Oncology (2014) 10:9 (1611-1617)) (2014) (0)
1323 mTOR expression in gastrointestinal (GI) tract poorly differentiated endocrine carcinoma (PDEC) (2009) (0)
Adriamycin Used in Combination with Conventional Agents in the Treatment of Solid Tumors (1975) (0)
An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review (2010) (0)
Effect of age on treatment outcome to palonosetron (PALO) plus 1-day dexamethasone (DEX) for the prevention of nausea and vomiting in women receiving anthracycline plus cyclophosphamide (AC)-based chemotherapy: A meta-analysis of two phase III trials. (2011) (0)
[Lateral radiographic projection of the stomach in the study of malignant lymphomas]. (1973) (0)
2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with “non diffusive type” gastric carcinoma radically resected (2015) (0)
Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort (2014) (0)
Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data (2015) (0)
The Lateral Gastric X-ray Examination in Malignant Lymphomas. (1973) (0)
MERKEL CELL CARCINOMAAFTER LIVER TRANSPLANTATION: A CASE REPORT (2007) (0)
Erratum: Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (Melanoma Research (1999) 9, (503-509)) (2007) (0)
[Combined therapy of rectal tumors: the chemotherapy]. (2001) (0)
Insulin-like growth factor (IGF) components in postmenopausal metastatic breast cancer (MBC) patient having progressed on tamoxifen: different effect of exemestane (EXE) or megestrol acetate (MA) (2001) (0)
Hormonal-therapy in patients with stage-iv breast-cancer at diagnosis. (1995) (0)
Combined modality treatment in stage I and II diffuse non-Hodgkin's lymphomas. (1985) (0)
Efficacy of neoadjuvant toremifene (TOR) and intratumor expression of estrogen receptor (ER) Α and Β in elderly breast cancer (BC) patients. (2004) (0)
Immunostaining for c-kit (CD117) in well differentiated and poorly differentiated neuroendocrine tumors. (2004) (0)
Chapter 14 – NON-HODGKIN'S LYMPHOMAS: MILAN STUDIES (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Emilio Bajetta?

Emilio Bajetta is affiliated with the following schools:

Emilio Bajetta's Academic­Influence.com Rankings

Emilio Bajetta's Degrees

Why Is Emilio Bajetta Influential?

Emilio Bajetta's Published Works

Published Works

What Schools Are Affiliated With Emilio Bajetta?

Emilio Bajetta's AcademicInfluence.com Rankings